69998-14-7

Usage

Uses

Used in Organic Synthesis:
1-(propan-2-yl)pyrimidine-2,4,6(1H,3H,5H)-trione is used as a building block in organic synthesis for constructing more complex molecules. Its unique trione functional group and reactivity facilitate the creation of a variety of chemical compounds with diverse properties and applications.
Used in Pharmaceutical Research:
In pharmaceutical research, 1-(propan-2-yl)pyrimidine-2,4,6(1H,3H,5H)-trione is employed as a key component in the development of new drugs and therapeutic agents. Its structural features and reactivity make it a valuable candidate for designing innovative pharmaceuticals with potential therapeutic benefits.
Used in Drug Development:
1-(propan-2-yl)pyrimidine-2,4,6(1H,3H,5H)-trione is utilized in drug development as a starting material or intermediate for synthesizing novel pharmaceuticals. Its unique structural features and reactivity contribute to the creation of new drug candidates with potential therapeutic effects.
Used in Industrial Applications:
1-(propan-2-yl)pyrimidine-2,4,6(1H,3H,5H)-trione may also have applications in various industrial fields, such as the production of specialty chemicals, materials, or other products. Its versatility and unique properties make it a valuable compound for diverse applications.
Used in Research and Development:
In research and development, 1-(propan-2-yl)pyrimidine-2,4,6(1H,3H,5H)-trione serves as a valuable chemical compound for exploring new reactions, mechanisms, and applications. Its unique structural features and reactivity provide opportunities for advancing scientific knowledge and discovering innovative applications in various fields.

Upstream product

• 691-60-1 N-isopropylurea 
• 105-53-3 diethyl malonate 
• 108-59-8 malonic acid dimethyl ester 

Downstream Products

• 1642288-47-8 6-{[(1S)-1-phenylethyl]amino}-3-(propan-2-yl)-1,2,3,4- tetrahydropyrimidine-2,4-dione 

Relevant academic research and scientific papers

METHODS OF TREATMENT WITH MYOSIN MODULATOR

Disclosed herein are methods of treatment comprising administering a therapeutically effective amount of a myosin modulator or a pharmaceutically acceptable salt thereof to a subject in need thereof and diagnostic methods useful in connection with those treatments. Due to observations unfolding in clinical trials with mavacamten and with mavacamten and other myosin inhibitors in the pre-clinical setting, new insights into how myosin inhibitors can be used beneficially to impact the disease state of HCM and other diseases are provided herein.

Myosin inhibitor, as well as preparation method and application thereof

The invention relates to the field of medicinal chemistry, in particular to a myosin inhibitor, as well as a preparation method and application thereof. The invention provides a compound or pharmacologically acceptable salt, an isomer, a prodrug, a polymorphic substance or a solvate thereof. A chemical structural formula of the compound is as shown in a formula I. Compared with other similar medicines in the prior art, the compound or the pharmacologically acceptable salt, the isomer, the prodrug, the polymorphic substance or the solvate thereof provided by the invention have better activity and a more ideal pharmacokinetics characteristic.

MAVACAMTEN FOR USE IN THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY

Provided are methods for treating hypertrophic cardiomyopathy and diastolic dysfunction.

BICYCLIC-PYRIMIDINEDIONE COMPOUNDS

The present invention provides novel bicyclic pyrimidinedione compounds that are useful for the treatment of hypertrophic cardiomyopathy (HCM) and conditions associated with left ventricular hypertrophy or diastolic dysfunction. The synthesis and characterization of the compounds is described, as well as methods for treating HCM and other forms of heart disease.

CYCLOALKYL-SUBSTITUTED PYRIMIDINEDIONE COMPOUNDS

The present invention provides novel cycloalkyl-substituted pyrimidine dione compounds that are useful for the treatment of hypertrophic cardiomyopathy (HCM) and conditions associated with left ventricular hypertrophy or diastolic dysfunction. The synthesis and characterization of the compounds is described, as well as methods for treating HCM and other forms of heart disease.

PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS

Provided are novel pyrimidine dione compounds and pharmaceutically acceptable salts thereof, that are useful for the treatment of hypertrophic cardiomyopathy (HCM) and conditions associated with left ventricular hypertrophy or diastolic dysfunction. The synthesis and characterization of the compounds and pharmaceutically acceptable salts thereof, are described, as well as methods for treating HCM and other forms of heart disease.

Di- or trisubstituted xanthines with neuroleptic properties and composition

The invention relates to xanthines corresponding to the formula STR1 and physiologically acceptable salts thereof, in which R1 represents C2 -C4 -alkyl, C3 -C4 -isoalkyl, CH2 -(C2 -C3 -alkenyl) or CH2 -(C3 -isoalkenyl); R3 represents C3 -C5 -alkyl, C3 -C5 -isoalkyl, CH2 -(C2 -C4 -alkenyl) or CH2 -(C3 -C4 -isoalkenyl); R8 represents H, methyl or ethyl; with the proviso that (1) when R8 represents H, R1 is allyl and (2) R1 and R3 cannot both represent butyl or allyl at the same time. The compounds show non-specific or anxiolytic sedative activity.